Mannkind reported $62.52M in Cash and Equivalent for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acceleron Pharma XLRN:US $ 336.2M 119.31M
Adamas Pharmaceuticals ADMS:US 88.8M 36.03M
Adma Biologics ADMA:US $ 42.41M 19.56M
Biocryst Pharmaceuticals BCRX:US $ 218.43M 8.47M
Biodelivery Sciences International BDSI:US 119.85M 3.42M
BioSpecifics Technologies BSTC:US 2.87M 14M
Chemocentryx CCXI:US $ 77.2M 8.66M
Dicerna Pharmaceuticals DRNA:US $ 221.21M 62.1M
Dynavax Technologies DVAX:US $ 129.61M 50.55M
Eli Lilly And LLY:US $ 3220M 217.6M
Flexion Therapeutics FLXN:US $ 107.63M 8.92M
Halozyme Therapeutics HALO:US $ 446.97M 52.48M
Immunogen IMGN:US $ 239.54M 43.58M
Insmed INSM:US $ 928.33M 518.58M
Karyopharm Therapeutics KPTI:US $ 141.31M 52.84M
Kindred Biosciences KIN:US $ 46.72M 33.8M
Macrogenics MGNX:US $ 188.97M 29.53M
Mannkind MNKD:US $ 62.52M 185.31M
Minerva Neurosciences NERV:US $ 74.22M 5.92M
Novavax NVAX:US $ 238.03M 4.68M
Peregrine Pharmaceuticals PPHM:US $ 159.69M 10.22M
Xencor XNCR:US $ 115.84M 61.12M